Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.

Haematologica - 1 Mar 2010

Koldehoff Michael, Kordelas Lambros, Beelen Dietrich W, Elmaagacli Ahmet H

Abstract excerpt

BACKGROUND: Selective inhibition of the BCR-ABL tyrosine kinase by RNA interference has been demonstrated in leukemic cells. We, therefore, evaluated specific BCR-ABL small interfering RNA silencing in BCR-ABL-positive cell lines, including those resistant to imatinib and particularly those with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Piperazines
Share to Benzamides
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Gene Expression Regulation, Leukemic

Share to Imatinib Mesylate

Share to Leukemia

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 20207846
DOI: 10.3324/haematol.2009.016063
PMCID: PMC2833068

Genes

BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20207846-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.PMID 20207846Read ↗

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)Semantic proximity Read ↗

Specific inhibition of bcr-abl gene expression by small interfering RNASemantic proximity Read ↗

Stable RNA interference (RNAi) as an option for anti-bcr-abl therapySemantic proximity Read ↗

Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemiaSemantic proximity Read ↗

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Semantic proximity Read ↗

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.Semantic proximity Read ↗

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.Semantic proximity Read ↗

SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinibSemantic proximity Read ↗

Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cellsSemantic proximity Read ↗

MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.Semantic proximity Read ↗

An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents.Semantic proximity Read ↗

Targeting primary human leukaemia cells with RNA interference: Bcr‐Abl targeting inhibits myeloid progenitor self‐renewal in chronic myeloid leukaemia cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.